Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C26H44NO6S.Na |
Molecular Weight | 521.6875 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 10 / 10 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@]([H])(CCC(=NCCS(=O)(=O)O)[O-])[C@@]1([H])CC[C@@]2([H])[C@]3([H])CC[C@]4([H])C[C@@]([H])(CC[C@]4(C)[C@@]3([H])C[C@@]([H])([C@]12C)O)O.[Na+]
InChI
InChIKey=YXHRQQJFKOHLAP-FVCKGWAHSA-M
InChI=1S/C26H45NO6S.Na/c1-16(4-9-24(30)27-12-13-34(31,32)33)20-7-8-21-19-6-5-17-14-18(28)10-11-25(17,2)22(19)15-23(29)26(20,21)3;/h16-23,28-29H,4-15H2,1-3H3,(H,27,30)(H,31,32,33);/q;+1/p-1/t16-,17-,18-,19+,20-,21+,22+,23+,25+,26-;/m1./s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/26759227Curator's Comment:: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/25664595 | https://www.ncbi.nlm.nih.gov/pubmed/23592128 | https://www.ncbi.nlm.nih.gov/pubmed/20522594
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26759227
Curator's Comment:: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/25664595 | https://www.ncbi.nlm.nih.gov/pubmed/23592128 | https://www.ncbi.nlm.nih.gov/pubmed/20522594
Sodium taurodeoxycholate is a bile salt-related, anionic detergent used for isolation of membrane proteins including inner mitochondrial membrane proteins. It is formed by the conjugation of ursodeoxycholic acid (UDCA) with taurine. Sodium taurodeoxycholate and ursodeoxycholic acid are major constituents of black bear bile, which has been used in traditional Chinese medicine for thousands of years. Bear bile was historically employed to treat a number of diseases including jaundice, summer diarrhea, abdominal pain due to hepatobiliary diseases and gastric malfunction, biliary ascariasis, infectious skin diseases, the common cold, intestinal worms, and inflammation of the throat. Sodium taurodeoxycholate has been shown to inhibit apoptosis by modulating mitochondrial membrane perturbation and pore formation, B cell lymphoma 2 (Bcl-2)-associated protein X (BAX) translocation, cytochrome c release, and caspase activation. Sodium taurodeoxycholate inhibits amyloid beta (Ab)-induced apoptosis and attenuates the endoplasmic reticulum (ER) stress, which are thought to be key components of the pathological process in certain diseases. In clinical studies, Sodium taurodeoxycholate is shown to be very safe with oral administration of 1500 mg/day for up to 6 months. In a more recent clinical study, a dose of 1750 mg/day for up to 4 weeks was well tolerated in healthy obese persons. One of the major adverse effects of Sodium taurodeoxycholate is diarrhea. Based on the related information from ursodeoxycholic acid, other gastrointestinal side effects are possible including abdominal pain, flatulence, nausea, dyspepsia, and anorexia.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL5409 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26435512 |
680.0 nM [EC50] | ||
Target ID: CHEMBL1743128 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12523936 |
60.0 µM [IC50] | ||
Target ID: CHEMBL4847 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12842829 |
|||
Target ID: gallbladder eicosanoid release Sources: https://www.ncbi.nlm.nih.gov/pubmed/7708818 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Inhibition of MRP1-mediated efflux in human erythrocytes by mono-anionic bile salts. | 2005 Sep-Oct |
|
Purification and characterization of the first reptile pancreatic lipase: the turtle. | 2008 Apr |
|
Store-operated Ca(2+) channels and Stromal Interaction Molecule 1 (STIM1) are targets for the actions of bile acids on liver cells. | 2008 May |
|
Loss of organic anion transporting polypeptide 1a1 increases deoxycholic acid absorption in mice by increasing intestinal permeability. | 2011 Dec |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25664595
Tauroursodeoxycholic acid 1 g twice daily by mouth
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9537871
Isolated rat hepatocytes were cultured in uncoated culture dishes (1x10^6 cells per plate) and treated with bile acids for 4 to 24 h. After treatment, the tissue-culture supernatant was harvested and assayed for enzymatic activity of lactate dehydrogenase (LDH) and aspartate aminotransferase (AST). Enzymatic activity was determined in accordance with standard techniques, using commercially available standard kits (Boehringer Mannheim, Germany).
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C83486
Created by
admin on Fri Jun 25 23:08:00 UTC 2021 , Edited by admin on Fri Jun 25 23:08:00 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
23664773
Created by
admin on Fri Jun 25 23:08:00 UTC 2021 , Edited by admin on Fri Jun 25 23:08:00 UTC 2021
|
PRIMARY | |||
|
C80659
Created by
admin on Fri Jun 25 23:08:00 UTC 2021 , Edited by admin on Fri Jun 25 23:08:00 UTC 2021
|
PRIMARY | |||
|
1180-95-6
Created by
admin on Fri Jun 25 23:08:00 UTC 2021 , Edited by admin on Fri Jun 25 23:08:00 UTC 2021
|
PRIMARY | |||
|
5PE424S83L
Created by
admin on Fri Jun 25 23:08:00 UTC 2021 , Edited by admin on Fri Jun 25 23:08:00 UTC 2021
|
PRIMARY | |||
|
1364852
Created by
admin on Fri Jun 25 23:08:00 UTC 2021 , Edited by admin on Fri Jun 25 23:08:00 UTC 2021
|
PRIMARY | RxNorm | ||
|
214-652-0
Created by
admin on Fri Jun 25 23:08:00 UTC 2021 , Edited by admin on Fri Jun 25 23:08:00 UTC 2021
|
PRIMARY |
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD